Cargando…
Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma
Low grade serous ovarian carcinoma (LGSOC) demonstrates unique clinical and molecular features compared to other ovarian cancer types. The relationship between common histological features of LGSOC and molecular events, such as hormone receptor expression patterns and MAPK gene mutation status, rema...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175560/ https://www.ncbi.nlm.nih.gov/pubmed/37169775 http://dx.doi.org/10.1038/s41598-023-34627-5 |
_version_ | 1785040234490101760 |
---|---|
author | Hollis, Robert L. Thomson, John P. van Baal, Juliette Ilenkovan, Narthana Churchman, Michael van de Vijver, Koen Dijk, Frederike Meynert, Alison M. Bartos, Clare Rye, Tzyvia Croy, Ian Diana, Patricia van Gent, Mignon Creedon, Helen Nirsimloo, Rachel Lok, Christianne Gourley, Charlie Herrington, C. Simon |
author_facet | Hollis, Robert L. Thomson, John P. van Baal, Juliette Ilenkovan, Narthana Churchman, Michael van de Vijver, Koen Dijk, Frederike Meynert, Alison M. Bartos, Clare Rye, Tzyvia Croy, Ian Diana, Patricia van Gent, Mignon Creedon, Helen Nirsimloo, Rachel Lok, Christianne Gourley, Charlie Herrington, C. Simon |
author_sort | Hollis, Robert L. |
collection | PubMed |
description | Low grade serous ovarian carcinoma (LGSOC) demonstrates unique clinical and molecular features compared to other ovarian cancer types. The relationship between common histological features of LGSOC and molecular events, such as hormone receptor expression patterns and MAPK gene mutation status, remains poorly understood. Recent data suggest some of these molecular features may be biomarkers of response to recently introduced biologically-targeted therapies, namely endocrine therapy and MEK inhibitors. We utilize a cohort of 63 pathologically-confirmed LGSOC cases with whole exome sequencing and hormone receptor expression data to investigate these relationships. LGSOC cases demonstrated uniformly high oestrogen receptor (ER) expression, but variable progesterone receptor (PR) expression intensity. 60% and 37% of cases demonstrated micropapillary and macropapillary patterns of stromal invasion, respectively. 63% of cases demonstrated desmoplasia, which was significantly associated with advanced disease stage and visible residual disease after cytoreductive surgery. MAPK-mutant cases (KRAS, BRAF, NRAS) more frequently demonstrated macropapillary stromal invasion, while Chr1p loss was associated with desmoplasia and low PR expression. Presence of micropapillary stromal invasion and low PR expression were associated with significantly poorer survival after accounting for stage and residual disease status. Together, these data identify novel relationships between histopathological features and molecularly-defined subgroups in LGSOC. |
format | Online Article Text |
id | pubmed-10175560 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-101755602023-05-13 Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma Hollis, Robert L. Thomson, John P. van Baal, Juliette Ilenkovan, Narthana Churchman, Michael van de Vijver, Koen Dijk, Frederike Meynert, Alison M. Bartos, Clare Rye, Tzyvia Croy, Ian Diana, Patricia van Gent, Mignon Creedon, Helen Nirsimloo, Rachel Lok, Christianne Gourley, Charlie Herrington, C. Simon Sci Rep Article Low grade serous ovarian carcinoma (LGSOC) demonstrates unique clinical and molecular features compared to other ovarian cancer types. The relationship between common histological features of LGSOC and molecular events, such as hormone receptor expression patterns and MAPK gene mutation status, remains poorly understood. Recent data suggest some of these molecular features may be biomarkers of response to recently introduced biologically-targeted therapies, namely endocrine therapy and MEK inhibitors. We utilize a cohort of 63 pathologically-confirmed LGSOC cases with whole exome sequencing and hormone receptor expression data to investigate these relationships. LGSOC cases demonstrated uniformly high oestrogen receptor (ER) expression, but variable progesterone receptor (PR) expression intensity. 60% and 37% of cases demonstrated micropapillary and macropapillary patterns of stromal invasion, respectively. 63% of cases demonstrated desmoplasia, which was significantly associated with advanced disease stage and visible residual disease after cytoreductive surgery. MAPK-mutant cases (KRAS, BRAF, NRAS) more frequently demonstrated macropapillary stromal invasion, while Chr1p loss was associated with desmoplasia and low PR expression. Presence of micropapillary stromal invasion and low PR expression were associated with significantly poorer survival after accounting for stage and residual disease status. Together, these data identify novel relationships between histopathological features and molecularly-defined subgroups in LGSOC. Nature Publishing Group UK 2023-05-11 /pmc/articles/PMC10175560/ /pubmed/37169775 http://dx.doi.org/10.1038/s41598-023-34627-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Hollis, Robert L. Thomson, John P. van Baal, Juliette Ilenkovan, Narthana Churchman, Michael van de Vijver, Koen Dijk, Frederike Meynert, Alison M. Bartos, Clare Rye, Tzyvia Croy, Ian Diana, Patricia van Gent, Mignon Creedon, Helen Nirsimloo, Rachel Lok, Christianne Gourley, Charlie Herrington, C. Simon Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma |
title | Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma |
title_full | Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma |
title_fullStr | Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma |
title_full_unstemmed | Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma |
title_short | Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma |
title_sort | distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175560/ https://www.ncbi.nlm.nih.gov/pubmed/37169775 http://dx.doi.org/10.1038/s41598-023-34627-5 |
work_keys_str_mv | AT hollisrobertl distincthistopathologicalfeaturesareassociatedwithmolecularsubtypesandoutcomeinlowgradeserousovariancarcinoma AT thomsonjohnp distincthistopathologicalfeaturesareassociatedwithmolecularsubtypesandoutcomeinlowgradeserousovariancarcinoma AT vanbaaljuliette distincthistopathologicalfeaturesareassociatedwithmolecularsubtypesandoutcomeinlowgradeserousovariancarcinoma AT ilenkovannarthana distincthistopathologicalfeaturesareassociatedwithmolecularsubtypesandoutcomeinlowgradeserousovariancarcinoma AT churchmanmichael distincthistopathologicalfeaturesareassociatedwithmolecularsubtypesandoutcomeinlowgradeserousovariancarcinoma AT vandevijverkoen distincthistopathologicalfeaturesareassociatedwithmolecularsubtypesandoutcomeinlowgradeserousovariancarcinoma AT dijkfrederike distincthistopathologicalfeaturesareassociatedwithmolecularsubtypesandoutcomeinlowgradeserousovariancarcinoma AT meynertalisonm distincthistopathologicalfeaturesareassociatedwithmolecularsubtypesandoutcomeinlowgradeserousovariancarcinoma AT bartosclare distincthistopathologicalfeaturesareassociatedwithmolecularsubtypesandoutcomeinlowgradeserousovariancarcinoma AT ryetzyvia distincthistopathologicalfeaturesareassociatedwithmolecularsubtypesandoutcomeinlowgradeserousovariancarcinoma AT croyian distincthistopathologicalfeaturesareassociatedwithmolecularsubtypesandoutcomeinlowgradeserousovariancarcinoma AT dianapatricia distincthistopathologicalfeaturesareassociatedwithmolecularsubtypesandoutcomeinlowgradeserousovariancarcinoma AT vangentmignon distincthistopathologicalfeaturesareassociatedwithmolecularsubtypesandoutcomeinlowgradeserousovariancarcinoma AT creedonhelen distincthistopathologicalfeaturesareassociatedwithmolecularsubtypesandoutcomeinlowgradeserousovariancarcinoma AT nirsimloorachel distincthistopathologicalfeaturesareassociatedwithmolecularsubtypesandoutcomeinlowgradeserousovariancarcinoma AT lokchristianne distincthistopathologicalfeaturesareassociatedwithmolecularsubtypesandoutcomeinlowgradeserousovariancarcinoma AT gourleycharlie distincthistopathologicalfeaturesareassociatedwithmolecularsubtypesandoutcomeinlowgradeserousovariancarcinoma AT herringtoncsimon distincthistopathologicalfeaturesareassociatedwithmolecularsubtypesandoutcomeinlowgradeserousovariancarcinoma |